3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
20
Breast Neoplasms
11
Prostatic Neoplasms
10
Fallopian Tube Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Pancreatic Neoplasms
6
Triple Negative Breast Neoplasms
4
Endometrial Neoplasms
4
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Sarcoma
1
SCLC,Extensive Stage
1
Recurrence
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Penile Neoplasms
1
Interventions
Carboplatin
5
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
sarilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
niraparib
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled